November 20th 2024
Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.
November 15th 2024
November 11th 2024
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Lilly to Invest $72 Million for Insulin Manufacturing Upgrade
October 23rd 2017The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.